A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol

PHASE4CompletedINTERVENTIONAL
Enrollment

232

Participants

Timeline

Start Date

June 30, 2003

Study Completion Date

March 31, 2004

Conditions
Dyslipidemias
Interventions
DRUG

Atorvastatin

In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

DRUG

Atorvastatin

In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.

Trial Locations (17)

1180

Pfizer Investigational Site, Brussels

2018

Pfizer Investigational Site, Antwerp

2170

Pfizer Investigational Site, Merksem

2610

Pfizer Investigational Site, Wilrijk

2640

Pfizer Investigational Site, Mortsel

2650

Pfizer Investigational Site, Edegem

2800

Pfizer Investigational Site, Mechelen

2930

Pfizer Investigational Site, Brasschaat

4000

Pfizer Investigational Site, Liège

4100

Pfizer Investigational Site, Seraing

6060

Pfizer Investigational Site, Gilly (charleroi)

7100

Pfizer Investigational Site, La Louvière

8750

Pfizer Investigational Site, Wingene

8800

Pfizer Investigational Site, Roeselare

8930

Pfizer Investigational Site, Menen

9000

Pfizer Investigational Site, Ghent

B-3600

Pfizer Investigational Site, Genk

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00644670 - A Study Of The Efficacy Of Atorvastatin For Lowering Cholesterol In High-Risk Patients With High Cholesterol | Biotech Hunter | Biotech Hunter